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Venovenous extracorporeal membrane oxygenation (VV ECMO) is a therapeutic option to bridge patients with advanced lung disease to lung
transplantation. The use of VV ECMO avoids the use of mechanical ventilation while allowing patients to participate in physical therapy and to eat
normally while receiving respiratory support. We describe the successful use of ambulatory single-venous VV ECMO as a bridge to bilateral lung
transplantation in 4 patients with end-stage lung disease due to cystic fibrosis who developed acute hypercapnic respiratory failure. The use of
ambulatory single-venous VV ECMO was safe and effective in this small cohort of CF patients. Based on our experiences, our belief is that a key
step in the treatment course was early application of VV ECMO soon after development of acute respiratory failure requiring mechanical
ventilation.
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Lung transplantation is a life-prolonging therapeutic proce-
dure that is often performed in patients with cystic fibrosis (CF)
with end-stage lung disease. Declining lung function in CF
patients can lead to acute hypoxemic or hypercapnic respiratory
failure requiring respiratory support by mechanical ventilation.
There is evidence that mechanical ventilation before lung
transplantation often leads to multiple organ failure and is a
significant risk factor for mortality after transplantation; [1]
therefore, mechanical ventilation is considered a contraindica-
tion by many lung transplant programs. In severe cases where
patients develop respiratory failure refractory to conventional
ventilation, respiratory support with extracorporeal gas ex-
change can be attempted to wean from ventilation. Extracor-☆ There is no conflict of interest for any of the authors with any companies/organ
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oxygenation (ECMO), allow patients to be extubated while
optimizing nutrition and rehabilitation and avoiding complica-
tions of long-term mechanical ventilation; therefore, these
patients are “bridged” to lung transplantation.
Despite very limited research and mixed results, ECMO
continues to be used in the lung transplantation population. In
fact, ECMO was recently recognized as a rescue therapy for
severe primary graft dysfunction (PGD) after lung transplantation
[1]. Early institution of ECMO may lead to diminished mortality
in the setting of acute lung injury despite the high incidence of
multiple-organ failure [2]. A review of the Extracorporeal Life
Support Organization registry demonstrated a survival rate of
42% (63/151) in lung transplant recipients (age 35±18 years)
with PGD [3]. Both venoarterial (VA) and venovenous (VV)izations whose products/services may be discussed in this article.
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depending on patient oxygenation status, hemodynamic stability,
and surgeon preference. Although ECMO is now a recognized
treatment in PGD, its use as a “bridge” to lung transplantation has
been sporadic with mixed outcomes [4–16]. More recently,
Haneya and colleagues reported successful outcomes with the
selected use of different extracorporeal circulatory systems,
including VA or VV ECMO and pumpless extracorporeal lung
assist (PECLA), also known as arterio-venous CO2 removal
(AVCO2R), as a bridge to lung transplantation [17]. The
investigators changed from one extracorporeal circulatory
systems modality to another modality based on the clinical
status of the patients [17]. Successful short-term outcomes
included 7/10 successfully bridged to transplant with 5/7
discharged [17]. Recent developments demonstrated that a
single-venous cannulation in VV ECMO was a promising
technique as an alternative to current cannulation strategies in
patients requiring prolonged support and specifically for those
considered for bridging to lung transplantation [18]. The strategy
for single-venous VV ECMO (Fig. 1) has become easier with the
development of a bi-caval dual lumen catheter, which is inserted
from the right jugular vein into the superior vena cava, traversing
the right atrium with the distal tip sitting in the inferior vena cava.
The catheter drains venous blood from both the superior and
inferior vena cava, directing oxygenated blood into the right
atrium towards the tricuspid valve.
Limited data exists involving the use of VV ECMO as a
bridge to lung transplantation specifically in CF. As their
respiratory status deteriorates, CF patients with advanced lungPump
Oxygenator
Fig. 1. Single-venous VV ECMO with blood flow (arrows) as illustrated with a
bi-caval dual lumen catheter inserted from the right jugular vein into the superior
vena cava, traversing the right atrium to the inferior vena cava.disease become deconditioned with nutritional failure; there-
fore, treatment with mechanical ventilation during acute
respiratory failure may complicate their clinical course due to
the need for sedation and paralytics which would prevent
rehabilitation and provision of nutrition by enteral feedings
through artificial means. Therefore, ambulatory VV ECMO has
the potential to prevent the need for continuous mechanical
ventilation to allow optimal rehabilitation and oral nutrition
while avoiding sedation and paralytics in these patients awaiting
lung transplantation. We present our experiences in 4 young
adults with advanced CF lung disease who underwent
successful emergent lung transplantation while being treated
with ambulatory single-venous VV ECMO.
2. Description
This was an observational, retrospective review of CF
patients at the University of Kentucky and the University of
California at San Francisco who received VV ECMO as a
bridge to lung transplantation after endotracheal intubation for
acute respiratory failure with approval by the Institutional
Review Board at the 2 respective institutions. The diagnosis of
CF was based on characteristic pulmonary and gastrointestinal
symptoms plus an abnormal sweat chloride test result or cystic
fibrosis transmembrane regulator (CFTR) genotype.
Prior to implementation of VV ECMO, mechanical ventila-
tion used for therapy was standard pressure regulated volume
control ventilation and was used with low levels (5 to 10 cm
H2O) of positive end-expiratory pressure (PEEP). To administer
VV ECMO, a 23 or 27 Fr bi-caval dual lumen catheter (Avalon
Laboratories, LLC, Los Angeles, CA) was placed in the
operating room by the attending cardiothoracic surgeon via the
right internal jugular vein with the use of transesophageal
echocardiogram as seen in Fig. 2. There were no complications
encountered with the initial placement of the catheter and no
issues of dislodgement. The ECMO system consisted of a
centrifugal pump (Rotaflow; Maquet Cardiopulmonary-AG,
Hirrlingen, Germany) with an integrated battery for transport, a
polymethylpentene membrane oxygenator (PLSQuadroxD;
Maquet Cardiopulmonary-AG), which avoided plasma leakage
and had a total gas exchange surface of 1.8 m [2] with a very
low inherent resistance. The filling volume of the complete
device was between 400 and 500 mL. There were no episodes
of sepsis with VV ECMO in the small cohort, and antic-
oagulation was used continuously without significant bleeding.
Each patient also underwent placement of tracheostomy for
airway protection in case of mechanical ventilation and was
needed in the event of the loss of the extracorporeal circuit
along with ease of bronchoscopy for pulmonary toilet. A unique
aspect in the care of this cohort compared to other studies using
VV ECMO as a bridge to lung transplantation was the
decannulation of each patient at implantation.
3. Evaluation
A total of 4 CF patients with end-stage lung disease, who
developed acute hypercapnic respiratory failure, were bridged
Fig. 2. Chest X-ray demonstrating placement of bi-caval dual lumen catheter
with transesophageal echocardiography.
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outlines the demographics of the cohort, including the severity
of their underlying lung disease prior to transplant based on
measurement of forced expiratory volume in 1 s (FEV1). Mean
age of the cohort was 27.5±4.8 years (±SD) (range 23–34).
After hospitalization for acute exacerbation of their chronic
bronchial bacterial infection, each patient continued to have
respiratory decline despite optimal treatment with intravenous
antibiotics and escalation of airway clearance. Non-invasiveTable 1
Patient demographics.
Characteristic All patients
Age (years) 27.5±4.8 years ⁎
Race
Caucasian 4
Gender
Male 2
Female 2
Genotype
ΔF508/ΔF508 3
ΔF508/Other 1
Body mass index 18.7±1.1 ⁎
Pre-transplant
FEV1 (liters) 0.68±0.14 ⁎
FEV1 (% predicted) 20.8±5.5 ⁎
Post-transplant (2–3 months)
FEV1 (liters) 2.35±0.14 ⁎
FEV1 (% predicted) 69.8±5.6 ⁎
⁎ Mean±SD.respiratory support was attempted but provided limited benefit;
subsequently, each patient required endotracheal intubation and
mechanical ventilation. Due to refractory hypercapnia, all 4
patients were ultimately bridged to lung transplantation with
single-venous VV ECMO. Table 2 summarizes the initial
findings on arterial blood gas for each patient during the
transition from non-invasive support to mechanical ventilation
and then single-venous VV ECMO. There was improvement in
the hypercapnia with mechanical ventilation in 3 patients while
one patient experienced worsening hypercarbia with this patient
having the most severe airway obstruction at baseline. As a
result of mechanical ventilation, 2 patients developed pneu-
mothoraces and one patient developed a bronchopleural fistula.
Respiratory support with single-venous VV ECMO allowed
each patient to ambulate and perform physical therapy (Fig. 3)
and receive oral nutrition with a regular diet. There was no need
for sedation or paralytics. There were no bleeding complications
as a result of the anticoagulation needed for the ECMO circuit.
Each patient underwent successful emergent bilateral
sequential lung transplant with mean wait time of 8.5 days
(range 2–15 days) while on single-venous VV ECMO. Hospital
length of stay from the point of transplant to discharge was
18.3 days (range 15–22 days). The clinic visit 2–3 months after
hospital discharge from lung transplant visit demonstrated
significant improvement in pulmonary function based on FEV1
of 2.35±0.14 L or 69.8±5.6% predicted for the cohort
(Table 1).
4. Discussion
The first attempt to apply a pump oxygenator as cardiopul-
monary bypass was performed in 1951 where 40 min of total
bypass was used with the support of a rotating screen oxygenator
during open heart surgery [19]. The use of ECMO as a bridge to
lung transplantation or re-transplantation has been limited with
only sporadic case reports and case series reported over the lastTable 2
Initial arterial blood gas analysis while receiving respiratory support.
Patient
1
Patient
2
Patient
3
Patient
4
Non-invasive positive pressure ventilation
pH 7.22 7.28 7.28 7.32
PaCO2 103 126 135 82
PaO2 140 251 256 276
Mechanical ventilation⁎ (PRVC mode,
TV=7±1 mL/kg, RR=16±1,
PEEP=5±1 cmH2O, FIO2=60±5%,
Plateau pressure 27±3 cmH2O)
pH 7.25 7.30 7.33 7.13
PaCO2 97 120 124 137
PaO2 100 108 103 102
VV ECMO
pH 7.27 7.31 7.37 7.48
PaCO2 79 97 105 57
PaO2 102 104 98 106
⁎PRVC = pressure regulated volume control, TV = tidal volume, RR = respiratory
rate, PEEP = positive end-expiratory pressure, FIO2 = fraction of inspired oxygen.
Fig. 3. Patient ambulating on a treadmill while on single-venous VV ECMO.
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transplantation occurred in 1975 and involved a patient with
post-traumatic respiratory failure who died 10 days after the
transplant due to sepsis, anastomostic dehiscence, and size
mismatch [20]. Subsequently, ECMO was used for the second
time in 1982 as a bridge to lung transplantation in a patient with
severe paraquat poisoning [21]. After lung transplantation, the
patient was successfully weaned from ECMO, but the paraquat
poisoning recurred, thus ECMO was reinstituted with the patient
eventually requiring a second lung transplant [21]. The patient
eventually died 93 days after the initial transplant from
complications of a tracheal-innominate artery fistula [21]. Prior
to 1975, a total of 6 other patients on ECMO were considered for
lung transplantation, but all died before donor lungs became
available.
During this early period of ECMO use, ischemic breakdown
of the bronchial anastomosis was a common cause of death in
lung transplant recipients [20]. Transplant programs eventually
considered ECMO and endotracheal intubation as contraindica-
tions to lung transplantation because it was thought to
compromise anastomotic healing [5]. These beliefs came
about from the poor outcomes for the initial lung transplants
attempted while patients were on ECMO [20,21]. During this
same time, the use of ECMO further declined as a result of a
randomized, controlled trial published by Zapol et al. [22] that
reported negative outcomes related to the use of ECMO for
respiratory failure in adult patients. As a result, ECMO use for
bridge to lung transplantation was scarce until the early 1990s
when the group from Hannover Medical School published thefirst report of long-term survival after using ECMO as a bridge to
lung re-transplantation [4]. Two patients were successfully re-
transplanted after 8 h and 232 h of ECMO support. Both patients
survived the re-transplantation with one patient having compli-
cations due to anastomotic problems requiring endotracheal
stents, cachexia, and several episodes of viral pneumonia with
death of the patient occurring 5 months post-transplant from
rejection, interstitial fibrosis, and interstitial pneumonia reported
on biopsy [4].
Subsequently in 1993, the group from the Hannover group
described the successful use of ECMO as a bridge to primary
transplant with a series of 3 cases where acute respiratory failure
was managed using VV ECMO [5]. The patients received 4, 5
and 9 days of ECMO before being listed for lung transplanta-
tion [5]. Lung transplantation was then performed after 5, 6 and
13 days of ECMO. One patient died intra-operatively, and the
other 2 patients were alive at 12 months after surgery [5].
Despite conflicting outcomes in clinical care, research has
continued in the area of ECMO and related technology. There
have been major advancements in the technical aspects of
ECMO and the circuit with new types of oxygenators being
developed and then used clinically. The more recently
developed membrane-type oxygenators are thought to be less
harmful where blood is exposed to oxygen through a gas-
permeable membrane to enhance gas transfer. At the end of the
1990s, a silicone covering of the microporous polypropylene
hollow fibers was used that had a heat exchanger and
oxygenating compartment with a polymethylpentene (PMP)
membrane in a small polycarbonate shell [23]. The develop-
ment of these PMP oxygenators is considered the most
important advancement in ECMO technology, since its
development is slowly replacing silicone membrane and
polypropylene microporous oxygenators that were used more
commonly before 2000 [24,25]. The PMP oxygenators require
less red blood cell and platelet transfusions, provide better gas
exchange, have lower resistance and priming volumes com-
pared to silicone membrane oxygenators and have less
oxygenator failure compared to polypropylene microporous
oxygenators [26]. The development of heparin-coated circuits
has made a significant impact with less platelet, complement,
and granulocyte activation with reduced heparin requirements
[27,28]. Another important advancement was the development
of new generation centrifugal pumps that have essentially no
risk of tubing rupture with a smaller priming volume and no
need for a reservoir [29].
In 2006, Fischer et al. [6] reported the first successful
outcomes with interventional lung assist NovaLung implanta-
tion as an effective bridge to lung transplantation. A total of 12
high-urgency recipients received the novel therapy with 4
patients dying of multiorgan failure (2 before and 2 after lung
transplantation), so 10 patients were successfully bridged to
lung transplantation while 8 were still alive at the time of
publication [6]. During the following year in 2007, Fisher et al.
[7] reported the initial experience with the interventional lung
assist (iLA) in a veno-venous pump-driven mode in 2 adult
patients (35-year-old with alveolitis and 38-year-old with CF)
with ventilator-refractory hypoxemia as a bridge to lung
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technology is available, extracorporeal circulatory systems are
used. Haneya and colleagues [16] reporting successful out-
comes in a fairly large cohort with 10 patients further
demonstrate the feasibility of prolonged extracorporeal circu-
latory systems support leading to successful lung transplanta-
tion. In fact, prolonged support over weeks or even months with
extracorporeal circulatory systems technology is now reported
[30].
The use of extracorporeal circulatory systems as a bridge to
lung transplantation remains controversial with success con-
tinuing to be reported in small cohorts of patients. Organ
shortages remain to be a significant problem with morality rates
approaching 20% for patients on the lung transplant wait list.
Prolonging the life of a suitable transplant candidate or treating
to allow recovery of acute failure with extubation using
extracorporeal circulatory systems increases the probability of
organ availability for transplantation. The challenge is how long
to support and maintain a candidate to allow comparable
outcomes to the general recipient population. The important
finding by Heneya and colleagues [17] was that matching the
physiologic need to the risk and benefits of the extracorporeal
circulatory systems technique (VA or VV ECMO and PECLA
or AVCO2R) used is vital in successful outcomes in patients
requiring a bridge to lung transplantation.
In this case series, ambulatory single-venous VV ECMOwas
very effective in bridging 4 CF patients to lung transplant
emergently. Each of these patients had end-stage lung disease
prior to their hospitalization, which made the decision easier to
bridge to transplant since their prognosis was already poor. The
application of ambulatory single-venous VV ECMO allowed
for rehabilitation with physical therapy permitted each patient to
eat normally. Post-transplant hospital length of stay was similar
to other patients, which we felt was likely due to the
rehabilitation and nutrition provided while on single-venous
VV ECMO. Ambulation was not complicated by the ECMO
circuit while each patient tolerated a regular diet without
problems until the time of transplant.
In conclusion, ambulatory single-venous VV ECMO is a
viable therapeutic option that should be considered as a bridge
to lung transplantation in CF patients with end-stage lung
disease, who developed acute hypercapnic respiratory failure.
Rehabilitation with physical therapy and the ability to eat
normally while being supported by ambulatory single-venous
VV ECMO prevented the need for sedation and paralytics while
also allowing recovery from pneuomothoraces that were
complicated by mechanical ventilation. Research is needed to
define if mechanical ventilation should be completely avoided
and to better describe when ambulatory single-venous VV
ECMO should be used for hypercapnic respiratory failure in CF
patients with advanced lung disease.
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